Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;50(10):1339-1342.
doi: 10.1111/1346-8138.16851. Epub 2023 Jun 8.

Biological and JAK inhibitor therapy outcomes for severe psoriasis in trisomy 21

Cathal O'Connor  1   2 , Berbie Byrne  3 , Darren Roche  1 , Garret O'Connell  4 , Michael O'Connell  4 , Michelle Murphy  1   2 , John Bourke  1 , Maeve Lynch  3 , Mary Bennett  1
Affiliations

Biological and JAK inhibitor therapy outcomes for severe psoriasis in trisomy 21

Cathal O'Connor et al. J Dermatol. 2023 Oct.

Abstract

Little is known about biological outcomes for severe psoriasis in trisomy 21 (T21). Our aim was to review outcomes of patients with T21 and severe psoriasis treated with biologic or Janus kinase inhibitors (JAKi). Information on demographics, co-morbidities, and therapeutic responses was retrospectively collated. Twenty-one patients were identified (mean age 24.7 years). Ninety percent (18/20) of TNFα inhibitor trials failed. Almost two-thirds (7/11) of patients achieved an adequate response with ustekinumab. All three patients treated with tofacitinib achieved an adequate response following at least three biologic failures. The mean number of biologic/JAKi therapies received was 2.1 with overall survival of 36%. Eighty-one percent (17/21) of patients required conversion from their index biologic treatment due to failure. In patients with T21 and severe psoriasis, failure of TNFα inhibition is common and ustekinumab therapy should be considered as first-line therapy. The role of JAKi is emerging.

Keywords: Psoriasis; arthritis; immunology; obesity; trisomy 21.

PubMed Disclaimer

References

REFERENCES

    1. Huggard D, Doherty DG, Molloy EJ. Immune dysregulation in children with down syndrome. Front Pediatr. 2020;8:73. Published 2020 Feb 27.
    1. Lam M, Lu JD, Elhadad L, Sibbald C, Alhusayen R. Common dermatologic disorders in down syndrome: systematic review. JMIR Dermatol. 2022;5:e33391.
    1. Weijerman ME, van Furth AM, van der Mooren MD, van Weissenbruch MM, Rammeloo L, Broers CJM, et al. Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with down syndrome. Eur J Pediatr. 2010;169:1195-9.
    1. Enos CW, Ramos VL, McLean RR, Lin TC, Foster N, Dube B, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona psoriasis registry. J Am Acad Dermatol. 2022;86:68-76.
    1. Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183:628-37.